InChIKey	MOTJMGVDPWRKOC-QPVYNBJUSA-N
Compound Name	Atrasentan
Canonical SMILES	CCCCN(CCCC)C(=O)CN1C[C@H](c2ccc3c(c2)OCO3)[C@@H](C(=O)O)[C@@H]1c1ccc(OC)cc1
Clinical Status	Data-mined Candidate
Targets (Human+Pathogen)	2
Pfam Stratification	Homologous
Avg pChEMBL	8.77
Source	ChEMBL;BindingDB

DrugBank ID	DB06199
Drug Name	Atrasentan
CAS Number	173937-91-2
Groups	approved investigational
ATC Codes	nan
Description	Atrasentan is a novel, selective endothelin A receptor antagonist (SERA).[L52855] In April 2025, atrasentan was granted accelerated approval by the FDA for the reduction of proteinuria in patients with primary IgA nephropathy, becoming the first endothelin A receptor antagonist to be approved for th...

---

Categories: Antineoplastic Agents Benzodioxoles Cytochrome P-450 CYP2B6 Inducers Cytochrome P-450 CYP2B6 Inducers (strength unknown) Cytochrome P-450 CYP2B6 Inhibitors Cytochrome P-450 CYP2B6 Inhibitors (strength unknown) Cytochrome P-450 CYP2C8 Inhibitors Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) Cytochrome P-450 CYP2C9 Inhibitors Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) Cytochrome P-450 Enzyme Inducers Cytochrome P-450 Enzyme Inhibitors Dioxoles Endothelin A Receptor Antagonists Endothelin Receptor Antagonists Heterocyclic Compounds, Fused-Ring OATP1B1/SLCO1B1 Inhibitors OATP1B1/SLCO1B1 Substrates OATP1B3 inhibitors OATP1B3 substrates P-glycoprotein inhibitors P-glycoprotein substrates Pyrrolidines

---

Cross-references: BindingDB: 50051007 ChEBI: 135810 CHEMBL9194 ChemSpider: 140321 PubChem:159594 RxCUI: 2710449 Wikipedia: Atrasentan ZINC: ZINC000003812144